Trials / Recruiting
RecruitingNCT06997029
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 234 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986500 | Specified dose of specified days |
| DRUG | Palbociclib | Specified dose on specified days |
| DRUG | Fulvestrant | Specified dose on specified days |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2028-12-14
- Completion
- 2028-12-14
- First posted
- 2025-05-30
- Last updated
- 2026-04-07
Locations
21 sites across 3 countries: United States, Denmark, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06997029. Inclusion in this directory is not an endorsement.